Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Cancer Res. 2021 Jun 9;81(17):4373–4384. doi: 10.1158/0008-5472.CAN-21-0301

Figure 2: Fundamental lessons and fruits from allo-HSCT.

Figure 2:

Top panel: allogeneic HSCT has been the first form of cancer immunotherapy to enter the clinical arena. Hematopoietic stem cells (HSCs) are collected from a donor, while the recipient undergoes conditioning therapy. Upon infusion into the patient, HSCs begin to proliferate and differentiate to repopulate the hematopoietic compartment in a process termed immune reconstitution. The donor-derived immune system is then responsible for long-term immune surveillance against disease recurrence. Bottom panel: allo-HSCT has profoundly influenced cancer immunotherapy in several aspects: for each of them, from top to bottom we report the original allo-HSCT finding, the key unanswered questions in the field and the subsequent extensions to modern day immunotherapy (bullet points). DLI: donor lymphocyte infusion; Ag: antigen; mHAg: minor histocompatibility antigen; GvL: graft vs. leukemia; GvHD: graft vs. host disease; CRS: cytokine release syndrome.